e-learning | Sotagliflozin with insulin for type 1 diabetes

2nd June 2020 by Louise Hudman

e-learning | Sotagliflozin with insulin for type 1 diabetes

This is a new guideline from NICE published in Feb 2020 advising that sotagliflozin can be used alongside insulin for type 1 diabetes.

Sotagliflozin is an SGLT1 and SGLT2 inhibitor. It is only licensed for type 1 diabetes, not for type 2 diabetes.

Dapagliflozin was endorsed by NICE in Aug 19 as a treatment for type 1 diabetes. Sotagliflozin has exactly the same restrictions on its use. It improves HbA1c, brings greater weight loss and improves quality of life. It is presumed that this drop in HbA1c will lead to a lower risk of complications from diabetes, though this hasn’t yet been shown.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I don’t normally do this, but just to say that I thought your article at the front of the latest NASGP magazine about clinical errors was really excellent. Great, and very thoughtful writing. NASGP member."

‘Great, and very thoughtful writing’

‘Great, and very thoughtful writing’

See the full list of features within our NASGP membership plans

Membership